Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Tazarotene
Overview
What is Tazarotene?
Tazarotene Cream, 0.1% is for topical use and contains the active ingredient, tazarotene. Each gram of Tazarotene Cream, 0.1% contains 1 mg of tazarotene, in a white cream base.
Tazarotene is a member of the acetylenic class of retinoids. Chemically, tazarotene is ethyl 6-[(4,4-dimethylthiochroman- 6-yl)ethynyl]nicotinate. The compound has an empirical formula of C
H
NO
S and molecular weight of 351.46. The structural formula is shown below:
Tazarotene Cream contains the following inactive ingredients: benzyl alcohol 1%; carbomer copolymer type A; carbomer homopolymer type B; edetate disodium; medium chain triglycerides; mineral oil; purified water; sodium hydroxide; sodium thiosulfate; and sorbitan monooleate.
What does Tazarotene look like?
What are the available doses of Tazarotene?
Cream, 0.1%. (
)
What should I talk to my health care provider before I take Tazarotene?
How should I use Tazarotene?
Tazarotene Cream, 0.1% is indicated for the topical treatment of patients with plaque psoriasis.
Tazarotene Cream is for topical use only. Tazarotene Cream is not for ophthalmic, oral, or intravaginal use. If contact with mucous membranes occurs, rinse thoroughly with water
.
Wash hands thoroughly after application.
What interacts with Tazarotene?
Sorry No Records found
What are the warnings of Tazarotene?
Sorry No Records found
What are the precautions of Tazarotene?
Sorry No Records found
What are the side effects of Tazarotene?
Sorry No records found
What should I look out for while using Tazarotene?
Tazarotene Cream is contraindicated in:
What might happen if I take too much Tazarotene?
Excessive topical use of Tazarotene Cream, 0.1% may lead to marked redness, peeling, or discomfort
.
Tazarotene Cream, 0.1% is not for oral use. Oral ingestion of the drug may lead to the same adverse effects as those associated with excessive oral intake of Vitamin A (hypervitaminosis A) or other retinoids. If oral ingestion occurs, the patient should be monitored, and appropriate supportive measures should be administered as necessary.
How should I store and handle Tazarotene?
Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature]Tazarotene Cream is a white cream available in a concentration of 0.1%. It is supplied in a collapsible aluminum tube with a white polypropylene screw cap. It is available in 30 g and 60 g sizes.Tazarotene Cream, 0.1% 30 g NDC 0713-0670-31 60 g NDC 0713-0670-60 Storage: Tazarotene Cream is a white cream available in a concentration of 0.1%. It is supplied in a collapsible aluminum tube with a white polypropylene screw cap. It is available in 30 g and 60 g sizes.Tazarotene Cream, 0.1% 30 g NDC 0713-0670-31 60 g NDC 0713-0670-60 Storage: Tazarotene Cream is a white cream available in a concentration of 0.1%. It is supplied in a collapsible aluminum tube with a white polypropylene screw cap. It is available in 30 g and 60 g sizes.Tazarotene Cream, 0.1% 30 g NDC 0713-0670-31 60 g NDC 0713-0670-60 Storage:
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Tazarotene is a retinoid prodrug which is converted to its active form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα RARβ, and RAR
, but shows relative selectivity for RARβ, and RAR
and may modify gene expression. The clinical significance of these findings is unknown.
Non-Clinical Toxicology
Tazarotene Cream is contraindicated in:Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.
Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in orally treated animals. Although there may be less systemic exposure in the treatment of acne of the face alone due to less surface area for application, tazarotene is a teratogenic substance, and it is not known what level of exposure is required for teratogenicity in humans .
There were thirteen reported pregnancies in subjects who participated in the clinical trials for topical tazarotene. Nine of the subjects were found to have been treated with topical tazarotene, and the other four had been treated with vehicle. One of the subjects who was treated with tazarotene cream elected to terminate the pregnancy for non-medical reasons unrelated to treatment. The other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies. As the exact timing and extent of exposure in relation to the gestation times are not certain, the significance of these findings is unknown.
Females of Child-bearing Potential
Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when Tazarotene Cream is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered.
A negative result for pregnancy test should be obtained within 2 weeks prior to Tazarotene Cream therapy. Tazarotene Cream therapy should begin during a menstrual period .
The following serious adverse reactions are discussed in more detail in other sections of the labeling:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).